This report by the Economist Intelligence Unit was commissioned by CMS. The report "explores the extent to which firms identify intangible assets as trade secrets and implement protective measures to safeguard them accordingly."
This is a sample IP assignment agreement, regarding the assignment of all rights (including copyrights) to works developed by the assignor. Initially published December 19, 2015, republished March 29, 2023.
In this multi-jurisdictional guide, explore an overview of key legal issues, rules and developments regarding copyright across a range of jurisdictions.
Check out this whitepaper developed by Foley & Lardner LLP to learn more about the top twelve trends in the digital assets space.
Canada is an attractive market for pharmaceutical manufacturers. Most Canadian consumers have some form of drug coverage through government programs and/or private insurance. Below are ten patent and regulatory topics that in-house counsel need to know before bringing an innovative product to Canada.
Editor's note: This article was updated to reflect recent developments; the original version of this article was published on December 16, 2020.
The September 2017 amendments to the Patented Medicines (Notice of Compliance) Regulations introduced a new scheme for pharmaceutical patent linkage litigation in Canada. That scheme is now much closer to the United States' (US) Hatch-Waxman scheme, but with remaining key differences that are explained in this chart.
Amendments to the Canadian Patent Act and enactment of the Certificate of Supplementary Protection Regulations flowing from the Canada-European Union (EU) Comprehensive Economic and Trade Agreement introduced a new framework in Canada for the issuance of Certificates of Supplementary Protection (CSPs).
This chart compare key aspects of the two regimes, Canada's and the EU's.
Under the US Patent and Trademark Office’s (USPTO) new guidance on discretionary denial of institution of inter partes and post-grant (IPR and PGR, respectively) proceedings, a pending International Trade Commission (ITC) investigation is no longer a basis for the Patent Trial and Appeals Board (PTAB) to exercise its discretion to deny institution. This is a material change from past PTAB practice, which had previously denied institution of such post-grant proceedings due to an ongoing parallel ITC proceeding. This article discusses three considerations for ITC litigants given the USPTO’s new guidance.
Learn how the European Union Intellectual Property Office study on AI and IP laws, published March 2, 2022, illustrates through hypothetical cases the "double-edged sword" of AI in IP protection and infringement.
This is a due diligence request list, in order to obtain IP-related information from a seller, in the context of an acquisition.